Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Scientists have identified a simple blood marker—the neutrophil to lymphocyte ratio (NLR)—that can detect Alzheimer’s and dementia risk years before someone experiences cognitive decline. Researchers at NYU Langone Health published this discovery in April 2026 in *Alzheimer’s & Dementia*, analyzing data from nearly 370,000 patients across multiple healthcare systems. What makes this finding significant is that it draws from a routine blood test most people already receive at their doctor’s office: a complete blood cell count.
The NLR measures the balance between two types of white blood cells—neutrophils, which rise during inflammation, and lymphocytes, which support immune defense. In this massive study, patients with higher NLR readings showed increased dementia risk, and the association was particularly strong in women and Hispanic populations. A 65-year-old woman with an elevated NLR might learn from her doctor that her blood work suggests she should discuss preventive strategies or monitoring for cognitive decline, even though she feels and thinks perfectly normally today.
Table of Contents
- How Can a Blood Test Predict Dementia Risk Before Symptoms Appear?
- What Does NLR Tell Us About Immune System Changes in Brain Disease?
- What Other Blood-Based Biomarkers Are Advancing Dementia Detection?
- How Can People Use NLR Results to Take Action Now?
- What Are the Limitations of Using a Single Blood Marker for Dementia Risk?
- How Does the NLR Finding Compare to Other Recent Dementia Biomarker Discoveries?
- What Does This Mean for the Future of Dementia Prevention?
- Conclusion
How Can a Blood Test Predict Dementia Risk Before Symptoms Appear?
The connection between NLR and dementia risk stems from what researchers observe in Alzheimer’s disease at the cellular level. Neutrophils—the most abundant white blood cells—become overactive and accumulate in the brains of people with Alzheimer’s pathology. In laboratory studies, elevated neutrophils actually accelerated disease progression in mouse models, suggesting that immune dysregulation is not just a consequence of dementia but potentially a driver of it. Because the blood-brain barrier becomes compromised early in Alzheimer’s disease, changes in circulating immune cells like neutrophils can reflect what’s happening inside the brain. The practical advantage is accessibility.
Unlike advanced brain imaging (PET scans) or spinal fluid biomarkers that require special procedures, the complete blood cell count is inexpensive, widely available, and already performed routinely during annual checkups or hospital stays. The NYU Langone study included data from patients at four of their hospitals plus 85,000 additional patients from the Veterans Health Administration, making this one of the largest validation studies of an Alzheimer’s biomarker to date. A person getting routine bloodwork at their primary care clinic has no need for special appointments or tests to gather the data needed to calculate their NLR. However, the study also revealed an important caveat: NLR alone is not a sufficient predictor. A high NLR doesn’t guarantee someone will develop dementia, nor does a normal NLR rule it out completely. The researchers found the test is most useful when combined with other known dementia risk factors like age, family history, apolipoprotein E (APOE) status, and cardiovascular health markers.
What Does NLR Tell Us About Immune System Changes in Brain Disease?
The discovery of NLR as a dementia indicator fits into a broader understanding that neuroinflammation—inflammation inside the brain—plays a central role in Alzheimer’s disease. For decades, researchers focused mainly on plaques and tangles, the protein hallmarks of Alzheimer’s. But in recent years, the immune system’s role has emerged as equally important. Microglial activation, neutrophil infiltration, and systemic inflammation all appear early in disease progression, sometimes before the hallmark brain changes are detectable. What researchers found particularly interesting is that the association between NLR and dementia differed by population.
The NLR correlation was stronger in women and in Hispanic patients than in other groups studied. This could reflect differences in immune response patterns, underlying genetic risk factors, or healthcare-related variables that weren’t fully captured in the data. The finding underscores an important limitation in dementia research: most biomarker studies have historically been conducted in predominantly white, male populations, so these newer insights about population differences represent progress but also mean we’re still learning how risk indicators apply across diverse groups. The limitation here is temporal: knowing someone has an elevated NLR today tells us about their current immune status and suggests risk, but it doesn’t tell us when or if they’ll develop cognitive symptoms. Some people with elevated NLR may never develop dementia; others might progress quickly. NLR is a risk indicator, not a diagnosis, and this distinction matters for how patients and doctors interpret the finding.
What Other Blood-Based Biomarkers Are Advancing Dementia Detection?
Beyond the NLR finding, proteomics—the study of all proteins expressed in the body—has emerged as another powerful tool for early disease detection. Research published in April 2026 showed that AI analysis of protein expression patterns can identify people at risk for dementia or Parkinson’s disease up to a decade before formal diagnosis. While the NLR is a single, simple ratio calculated from basic blood counts, proteomic approaches measure hundreds or thousands of different proteins and use artificial intelligence to find patterns that correlate with disease risk. For someone concerned about dementia prevention, this means that multiple pathways now exist for identifying risk early. A person might receive an elevated NLR result from their routine annual physical, prompting a discussion with their doctor about lifestyle interventions—exercise, cognitive engagement, sleep optimization, cardiovascular health, and dietary patterns like the Mediterranean diet.
Or they might opt for more advanced proteomics testing if available through their healthcare system, which could provide even earlier warning. The choice between these tests often depends on cost, availability, and the individual’s risk factors and preferences. The practical advantage of having multiple biomarkers is that they can validate each other. If someone has both an elevated NLR and proteomic markers suggesting dementia risk, the evidence becomes stronger, potentially prompting more aggressive preventive action. The tradeoff is complexity: more tests and more data can improve accuracy but also increases cost and the chance of false positives that cause unnecessary anxiety.
How Can People Use NLR Results to Take Action Now?
If someone’s blood work shows an elevated NLR, the next step isn’t alarm—it’s conversation with their primary care physician. The NYU Langone study identifies NLR as a risk indicator to be considered alongside other factors, not as a diagnostic tool. A doctor might recommend cognitive baseline testing to establish how you’re thinking today, so any future decline can be tracked. They might discuss blood pressure management, since cardiovascular health strongly influences dementia risk. They might ask detailed questions about sleep quality, physical activity, cognitive engagement, and diet. Lifestyle interventions remain the most evidence-based preventive strategies available today. Regular aerobic exercise, cognitive activities, social engagement, quality sleep, and Mediterranean-style eating have all been associated with slower cognitive aging.
Someone with an elevated NLR might use that result as motivation to implement or strengthen these habits rather than as a source of despair. One person might start a regular walking program; another might join a book club or language class; another might prioritize seven to eight hours of sleep. These changes don’t require expensive medications or procedures—they’re accessible to most people. The tradeoff is that lifestyle change requires sustained effort. Someone who gets an elevated NLR result but doesn’t follow through on preventive actions gains nothing from knowing the number. Conversely, someone who already exercises regularly, stays cognitively active, and manages their cardiovascular health may not need to make major changes even if their NLR is elevated. The value of the test lies in its potential to motivate action and guide medical monitoring, not in determining destiny.
What Are the Limitations of Using a Single Blood Marker for Dementia Risk?
One key limitation is that NLR reflects only immune system changes and doesn’t capture other pathological processes in Alzheimer’s disease. Amyloid-beta accumulation, tau protein tangles, neurodegeneration on brain imaging, and genetic factors all contribute to dementia risk independently. A person with a normal NLR can still develop dementia if other risk factors are present or if their brain pathology develops through different mechanisms. Conversely, some people with elevated NLR may never progress to cognitive impairment, either because they’re at the very early stages of subclinical disease that might take decades, or because they have protective factors the test doesn’t measure. Another limitation is that the NLR can be influenced by conditions unrelated to dementia. Infections, inflammatory diseases, smoking, certain medications, and even stress can elevate neutrophil counts.
A person recovering from pneumonia or managing rheumatoid arthritis might have a temporarily elevated NLR that says nothing about their Alzheimer’s risk. This highlights why combining NLR with other clinical information—symptoms, family history, imaging if indicated, and other biomarkers—is essential. The researchers themselves noted that NLR is most useful when integrated into a comprehensive risk assessment, not used in isolation. A practical warning: not all blood tests are created equal, and lab variation can affect NLR values. One healthcare system might report a range of 2-4 as normal, while another uses 1.5-3.5. If someone is concerned about their NLR, comparing values over time within the same lab is more meaningful than comparing absolute numbers across different laboratories.
How Does the NLR Finding Compare to Other Recent Dementia Biomarker Discoveries?
The NLR finding is notable for its accessibility, but it’s part of a broader landscape of dementia biomarkers advancing in 2026. Blood tests for phosphorylated tau variants (p-tau181, p-tau217) and plasma phosphorylated tau-217 are increasingly available and highly specific for Alzheimer’s pathology. These tests are more Alzheimer’s-specific than NLR but also more expensive and not yet standard in routine clinical practice. Someone whose doctor is concerned about dementia might receive an NLR result from standard bloodwork, then get more specific biomarker testing if that result warrants further investigation.
The NLR approach has a different strength: it’s already embedded in healthcare systems worldwide. Every hospital, clinic, and lab calculates complete blood cell counts. The infrastructure exists today. Unlike newer biomarkers that require specialized equipment or reagents, implementing NLR-based risk assessment requires only education and algorithms—teaching doctors and patients to recognize and act on elevated NLR as a dementia risk signal.
What Does This Mean for the Future of Dementia Prevention?
The discovery of NLR as a dementia indicator suggests that the era of personalized dementia risk assessment is arriving. Instead of waiting for cognitive symptoms to prompt evaluation, people increasingly will know their neurodegeneration risk status years in advance based on blood tests. This shifts dementia from a disease that’s diagnosed late (often after significant cognitive damage) to a risk state that can be identified early and potentially modified through targeted interventions.
The future likely involves combining multiple biomarkers—NLR, plasma phosphorylated tau, proteomics, imaging, and genetic data—into risk prediction algorithms that guide personalized prevention strategies. Some people might benefit from more aggressive medical interventions; others might focus on lifestyle change. The conversation between patients and doctors about dementia risk will happen earlier, potentially during middle age or even earlier, when lifestyle modifications have the greatest potential impact.
Conclusion
Scientists at NYU Langone Health have identified the neutrophil to lymphocyte ratio in routine blood tests as an indicator of Alzheimer’s and dementia risk before cognitive symptoms appear. This discovery, published in April 2026 and based on nearly 370,000 patients, offers a simple, accessible, and inexpensive tool for identifying who might benefit from preventive monitoring and intervention. The finding is particularly meaningful for women and Hispanic populations, in whom the association was stronger.
However, NLR is one piece of a larger puzzle. It works best when combined with other risk factors, and it requires appropriate interpretation by healthcare providers and informed action by patients. If you’re concerned about dementia risk, talking with your primary care physician about your blood work, cognitive baseline testing, and preventive strategies remains the most practical first step. The convergence of multiple biomarkers and the growing evidence for lifestyle prevention suggest we’re entering an era where dementia risk can be identified and addressed far earlier than ever before.
